ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 235,11
0,78%
Dow Jones
44 910,65
0,42%
DAX
19 626,45
1,05%
Brent Oil
71,98
-0,08%
Bitcoin
96 707,96
-0,80%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Virios Therapeutics Inc (VIRI)

  7. Virios Therapeutics Inc (VIRI) Actualités

VIRI

Virios Therapeutics (VIRI)

Virios Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VIRI
DateHeureSourceTitreSymboleSociété
21/11/202415h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
08/11/202414h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
17/10/202422h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
15/10/202422h19Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:VIRIVirios Therapeutics Inc
07/10/202414h06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRIVirios Therapeutics Inc
07/10/202413h05GlobeNewswire Inc.Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)NASDAQ:VIRIVirios Therapeutics Inc
08/08/202415h15GlobeNewswire Inc.Virios Therapeutics Announces Second Quarter 2024 Financial ResultsNASDAQ:VIRIVirios Therapeutics Inc
01/08/202415h41GlobeNewswire Inc.Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:VIRIVirios Therapeutics Inc
23/07/202415h15GlobeNewswire Inc.Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne CenterNASDAQ:VIRIVirios Therapeutics Inc
22/05/202419h30GlobeNewswire Inc.Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
20/05/202422h05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
20/05/202402h53GlobeNewswire Inc.Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
17/05/202422h10GlobeNewswire Inc.Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
09/05/202413h45GlobeNewswire Inc.Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
02/05/202415h15GlobeNewswire Inc.Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:VIRIVirios Therapeutics Inc
26/03/202414h15GlobeNewswire Inc.Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
08/03/202423h00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:VIRIVirios Therapeutics Inc
01/03/202415h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRIVirios Therapeutics Inc
29/02/202415h15GlobeNewswire Inc.Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRIVirios Therapeutics Inc
28/02/202419h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202415h15GlobeNewswire Inc.Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesNASDAQ:VIRIVirios Therapeutics Inc
02/02/202422h31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VIRIVirios Therapeutics Inc
22/01/202415h33Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VIRIVirios Therapeutics Inc
22/01/202415h00GlobeNewswire Inc.Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
02/01/202413h05GlobeNewswire Inc.Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
13/11/202313h05GlobeNewswire Inc.Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
06/11/202313h05GlobeNewswire Inc.Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023NASDAQ:VIRIVirios Therapeutics Inc
12/10/202313h05GlobeNewswire Inc.Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023NASDAQ:VIRIVirios Therapeutics Inc
18/09/202313h05GlobeNewswire Inc.Virios Therapeutics Announces Termination of At-The-Market Sales AgreementNASDAQ:VIRIVirios Therapeutics Inc
12/09/202313h05GlobeNewswire Inc.Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023NASDAQ:VIRIVirios Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRI

Dernières Valeurs Consultées

NASDAQ
JSYNW
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés

BLACK FRIDAY

ADVFN

Célébrons nos 25 ans Est 1999-2024

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Cours Euronext en temps réel et illimités sur le site. Carnet d'ordres Euronext en direct